Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphoma.

IF 2.2 4区 医学 Q3 HEMATOLOGY
Emily R Gordon, Seda Tolu, Brigit A Lapolla, Megan H Trager, Oluwaseyi Adeuyan, Manuel A Pazos, Ted Piorczynski, David DeStephano, Susan E Bates, Barbara Pro, Jennifer E Amengual, Larisa J Geskin
{"title":"Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphoma.","authors":"Emily R Gordon, Seda Tolu, Brigit A Lapolla, Megan H Trager, Oluwaseyi Adeuyan, Manuel A Pazos, Ted Piorczynski, David DeStephano, Susan E Bates, Barbara Pro, Jennifer E Amengual, Larisa J Geskin","doi":"10.1080/10428194.2025.2542941","DOIUrl":null,"url":null,"abstract":"<p><p>Management of advanced stage cutaneous T-cell lymphoma (CTCL) can be challenging due to lack of durable responses to currently available therapies and their side effects and toxicities. Romidepsin, a histone deacetylase inhibitor, and mogamulizumab, an anti-CCR4 monoclonal antibody, have demonstrated some efficacy as monotherapies, however, survival outcomes remain poor. This retrospective study evaluates the effectiveness of sequential romidepsin-mogamulizumab (Romi-Moga) therapy in 18 patients with advanced CTCL. The overall response rate was 67% in our cohort and time to next treatment was 15 months, which compared favorably to clinical trials of monotherapies. Patients who transitioned to mogamulizumab within one month of romidepsin discontinuation exhibited superior responses in skin, blood, and lymph nodes and longer time to next treatment. These findings suggest a potential beneficial effect of Romi-Moga therapy when administered in close sequence. Prospective studies are needed to validate these results and optimize treatment strategies.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-8"},"PeriodicalIF":2.2000,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2025.2542941","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Management of advanced stage cutaneous T-cell lymphoma (CTCL) can be challenging due to lack of durable responses to currently available therapies and their side effects and toxicities. Romidepsin, a histone deacetylase inhibitor, and mogamulizumab, an anti-CCR4 monoclonal antibody, have demonstrated some efficacy as monotherapies, however, survival outcomes remain poor. This retrospective study evaluates the effectiveness of sequential romidepsin-mogamulizumab (Romi-Moga) therapy in 18 patients with advanced CTCL. The overall response rate was 67% in our cohort and time to next treatment was 15 months, which compared favorably to clinical trials of monotherapies. Patients who transitioned to mogamulizumab within one month of romidepsin discontinuation exhibited superior responses in skin, blood, and lymph nodes and longer time to next treatment. These findings suggest a potential beneficial effect of Romi-Moga therapy when administered in close sequence. Prospective studies are needed to validate these results and optimize treatment strategies.

罗米地辛和莫加单抗序贯治疗晚期皮肤t细胞淋巴瘤。
由于目前可用的治疗方法及其副作用和毒性缺乏持久的反应,晚期皮肤t细胞淋巴瘤(CTCL)的管理可能具有挑战性。组蛋白去乙酰化酶抑制剂罗米地辛(roidepsin)和抗ccr4单克隆抗体莫加珠单抗(mogamulizumab)作为单一疗法已经显示出一定的疗效,然而,生存结果仍然很差。本回顾性研究评估了序贯罗米地辛-莫gamulizumab (Romi-Moga)治疗18例晚期CTCL患者的有效性。在我们的队列中,总缓解率为67%,到下一次治疗的时间为15个月,与单一治疗的临床试验相比,这是有利的。在罗米地辛停药后一个月内改用莫加珠单抗的患者在皮肤、血液和淋巴结方面表现出更好的反应,并且需要更长的时间才能进行下一次治疗。这些发现表明,如果按照紧密的顺序进行Romi-Moga治疗,可能会产生有益的效果。需要前瞻性研究来验证这些结果并优化治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Leukemia & Lymphoma
Leukemia & Lymphoma 医学-血液学
CiteScore
4.10
自引率
3.80%
发文量
384
审稿时长
1.8 months
期刊介绍: Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信